Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy

Clinical Cancer Research

Volumn 4, Issue 9, 1998, Pages 2119-2123

  Wood Jr , David P ^a   Beaman, Andrew ^a   Banerjee, Mousumi ^a   Powell, Isaac ^a   Pontes, Edson ^a   Cher, Michael L ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN THERAPY; ANTIGEN DETECTION; ARTICLE; BONE MARROW CELL; CANCER STAGING; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE MARROW; COMBINED MODALITY THERAPY; HUMANS; MALE; NEOADJUVANT THERAPY; NEOPLASM CIRCULATING CELLS; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 3543026260     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Epstein, J. I., Pizov, G., and Walsh, P. C. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer (Phila.), 71: 3582-3593, 1993.
2. Frazier, H. A., Robertson, J. E., Dodge, R. K., and Paulson, D. F. The value of pathologic factors in Predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer (Phila.), 71: 3993-4001, 1993.
3. Partin, A. W., Pearson, J. D., Landis, P. K., Carter, H. B., Pound, C. R., Clemens, J. Q., Epstein, J. I., and Walsh, P. C. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology, 43: 649-659, 1994.
4. Soloway, M., Sharifi, R., Wajsman, Z., McLeod, D., Wood, D., Puras-Baez, A., and the Lupron Depot Neoadjuvant Prostate Cancer Study Group. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxMO) prostate cancer. J. Urol., 154: 424-428, 1995.
5. Fair, W. R., and Scher, H. I. Neoadjuvant hormonal therapy plus surgery for prostate cancer: the MSKCC experience. Surg. Oncol. Clin. N. Am., 6: 831-846, 1997.
6. Labrie, F., Cusan, L., Gomez, J. L., Diamond, P., Suburu, R., Lemay, M., Tetu, B., Fradet, Y., Belanger, A., and Candas, B. Neoadjuvant hormonal therapy: the Canadian experience. Urology, 49 (Suppl.): 56-64, 1997.
7. Wood, D. P., Jr., Banks, E. R., Humphreys, S., and Rangnekar, V. M. Sensitivity of immunohistochemistry and polymerase chain reaction in detecting prostate cancer cells in bone marrow. J. Histochem. Cytochem., 42: 505-511, 1994.
8. Wood, D. P., Jr., Banks, E. R., Humphreys, S., McRoberts, J. W., and Rangnekar, V. M. Identification of bone marrow micrometastases in patients with prostate cancer. Cancer (Phila.), 74: 2533-2540, 1994.
9. Olsson, C. A., de Vries, G. M., Raffo, A. J., Benson, M. C., O'Toole, K., Cao, Y., Buttyan, R. E., and Katz, A. E. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. J. Urol., 155: 1557-1562, 1996.
10. Sokoloff, M. H., Tso, C. L., Kaboo, R., Nelson, S., Ko, J., Dorey, F., Figlin, R. A., Pang, S., deKemion, J., and Belldegrun, A. Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients. J. Urol., 156: 1560-1566, 1996.
11. Corey, E., Arfman, E. W., Oswin, M. M., Melchior, S. W., Tindall, D. J., Young, C. Y., Ellis, W. J., and Vessella, R. L. Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages. Urology, 50: 184-188, 1997.
12. Wood, D. P., Jr., and Banerjee, M. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J. Clin. Oncol., 15: 3451-3457, 1997.
13. Eisenberger, M., Crawford, E. D., McLeod, D., Hussain, M., Loehrer, P., and Blumenstein, B. The prognostic significance of prostate specific antigen (PSA) in stage D2 prostate cancer (PC) interim evaluation of intergroup study 0105. Proc. Am. Soc. Clin. Oncol., 14: 235, 1995.
14. Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., and Goodman, P. J. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med., 321: 419-424, 1989.
15. Schroeder, F. H., Hermanck, P., Denis, L., Fair, W. R., Gospodarowicz, M. K., and Pavone-Macaluso, M. The TNM classification of prostate cancer. Prostate, 4: 129-133, 1992.
16. Cline, E., Vánky, F., Galili, U., Vose, B. M., and Fopp, M. Separation and characteristics of tumor-infiltrating lymphocytes in man. In: I. P. Witz and M. D. Hanna, Jr. (eds.), Contemporary Topics in Immunobiology, pp. 79-107. New York: Plenum Publishing, 1980.
17. Aprikian, A. G., Fair, W. R., Reuter, V. E., Sogani, P., Herr, H., Russo, P., and Sheinfeld, J. Experience with neoadjuvant diethylstilboestrol and radical prostatectomy in patients with locally advanced prostate cancer. Br. J. Urol., 74: 630-636, 1994.
18. Labrie, F., Dupont, A., Cusan, L., Gomez, J., and Emond, J. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin. Invest. Med., 16: 499-509, 1993.
19. Van Poppel, H., De Ridder, D., Elgamal, A., Van de Voorde, W., Werbrouck, P., Ackaert, K., Oyen, R., Pittomvils, G., Baert, L., and members of the Belgian Uro-Oncological Study Group. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. J. Urol., 154: 429-434, 1995.
20. Soloway, M. S., Sharifi, R., Wajsman, Z., McLeod, D., and Wood, D. P., Jr. Radical prostatectomy alone vs. radical prostatectomy preceded by androgen blockade in cT2b prostate cancer. J. Urol., 157: 160, 1997.
21. Su, S. L., Heston, W. D., Perroti, M., Cookson, M. S., Stroumbakis, N., Huyrk, R., Edwards, E., Brander, B., Coke, J., Soloway, S., Lewis, A., and Fair, W. R. Evaluating neoadjuvant therapy effectiveness on systemic disease: use of a prostatic-specific membrane reverse transcription polymerase chain reaction. Urology, 49: (Suppl.): 95-101, 1997.